Evidence map›Paper›PMID 26398941›Full record

ArticleDisease models & mechanisms2015

T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice.

Ceri E Oldreive, Anna Skowronska, Nicholas J Davies, Helen Parry, Angelo Agathanggelou, Sergey Krysov, Graham Packham, Zbigniew Rudzki, Laura Cronin, Katerina Vrzalikova and 6 more

Abstract read
In one paragraph

Article in Disease models & mechanisms, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ceri E OldreiveSchool of Cancer Sciences, Department of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
Anna SkowronskaSchool of Cancer Sciences, Department of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
Nicholas J DaviesSchool of Cancer Sciences, Department of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
Helen ParrySchool of Cancer Sciences, Department of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
Angelo AgathanggelouSchool of Cancer Sciences, Department of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
Sergey KrysovCRUK Centre, Cancer Sciences Unit, University of Southampton, Southampton, SO16 6YD, UK.
Graham PackhamCRUK Centre, Cancer Sciences Unit, University of Southampton, Southampton, SO16 6YD, UK.
Zbigniew RudzkiDepartment of Pathology, Heart of England Hospital, Birmingham, B9 5SS, UK.
Laura CroninSchool of Biosciences, University of Birmingham, Birmingham, B15 2TT, UK.
Katerina VrzalikovaSchool of Cancer Sciences, Department of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
Paul MurraySchool of Cancer Sciences, Department of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
Elena OdintsovaSchool of Cancer Sciences, Department of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
Guy PrattSchool of Cancer Sciences, Department of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
A Malcolm R TaylorSchool of Cancer Sciences, Department of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
Paul MossSchool of Cancer Sciences, Department of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
Tatjana StankovicSchool of Cancer Sciences, Department of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK stankovT@adf.bham.ac.uk.

Funding

Cancer Research UK 14346
6 · The paper itself

Abstract

Chronic lymphocytic leukaemia (CLL) cells require microenvironmental support for their proliferation. This can be recapitulated in highly immunocompromised hosts in the presence of T cells and other supporting cells. Current primary CLL xenograft models suffer from limited duration of tumour cell engraftment coupled with gradual T-cell outgrowth. Thus, a greater understanding of the interaction between CLL and T cells could improve their utility. In this study, using two distinct mouse xenograft models, we investigated whether xenografts recapitulate CLL biology, including natural environmental interactions with B-cell receptors and T cells, and whether manipulation of autologous T cells can expand the duration of CLL engraftment. We observed that primary CLL xenografts recapitulated both the tumour phenotype and T-cell repertoire observed in patients and that engraftment was significantly shorter for progressive tumours. A reduction in the number of patient T cells that were injected into the mice to 2-5% of the initial number or specific depletion of CD8(+) cells extended the limited xenograft duration of progressive cases to that characteristic of indolent disease. We conclude that manipulation of T cells can enhance current CLL xenograft models and thus expand their utility for investigation of tumour biology and pre-clinical drug assessment.

Indexed as

Immunocompromised HostTumor MicroenvironmentAnimalsCD8-Positive T-LymphocytesCell ProliferationCells, CulturedCell SurvivalCoculture TechniquesCytotoxicity, ImmunologicGraft SurvivalHeterograftsHumansLeukemia, Lymphocytic, Chronic, B-CellLymphocyte ActivationLymphocyte DepletionLymphocytes, Tumor-InfiltratingCLLMouse modelT-cell depletion

Identifiers

PMID26398941
PMCPMC4631786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.